Search
Belapectin
go.drugbank.com/drugs/DB15125InvestigationalBelapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
Navtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Gancotamab
go.drugbank.com/drugs/DB14784InvestigationalGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. … Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Nerofe
go.drugbank.com/drugs/DB14786InvestigationalNerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Xentuzumab
go.drugbank.com/drugs/DB14871InvestigationalXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC))
ATX-914
go.drugbank.com/drugs/DB12673InvestigationalAxt914 is under investigation in clinical trial NCT00417261 (Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy
Nicotinamide Mononucleotide
go.drugbank.com/drugs/DB03227InvestigationalA nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]
PF-06459988
go.drugbank.com/drugs/DB14768InvestigationalPF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Furafylline
go.drugbank.com/drugs/DB14029ExperimentalFurafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for [theophylline].
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).